Should I buy or sell Autolus Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks .

What is Autolus Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 12 month price targets for Autolus Therapeutics' shares. Their AUTL share price targets range from $4.80 to $11.00. On average, they expect the company's stock price to reach $8.16 in the next year. This suggests a possible upside of 70.0% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts .

How have AUTL shares performed in 2024?

Autolus Therapeutics' stock was trading at $6.44 on January 1st, 2024. Since then, AUTL shares have decreased by 25.5% and is now trading at $4.80. View the best growth stocks for 2024 here .

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AUTL earnings forecast .

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.18.

What ETFs hold Autolus Therapeutics' stock?

ETFs with the largest weight of Autolus Therapeutics (NASDAQ:AUTL) stock in their portfolio include Harbor Disruptive Innovation ETF (INNO) . Range Cancer Therapeutics ETF (CNCR) .

What other stocks do shareholders of Autolus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE) , CRISPR Therapeutics (CRSP) , VBI Vaccines (VBIV) , GW Pharmaceuticals (GWPH) , ImmunoGen (IMGN) , Teva Pharmaceutical Industries (TEVA) , TG Therapeutics (TGTX) , AbbVie (ABBV) , Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD) .

When did Autolus Therapeutics IPO?

Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perpetual Ltd (0.84%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free AUTL Stock Alerts

$4.80

-0.04 (-0.83%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.79
▼
$5.25
50-Day Range: $4.80
▼
$7.25
52-Week Range: $1.61
▼
$7.45

Volume: 1.21 million shs
Average Volume: 1.51 million shs
Market Capitalization: $1.28 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.16

Get Autolus Therapeutics alerts:

Autolus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 70.0% Upside
$8.16 Price Target
Short Interest: Healthy
1.57% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.40
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.71) to ($0.57) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

413th out of 918 stocks

Biological Products, Except Diagnostic Industry

59th out of 147 stocks

3.4

Analyst's Opinion

Consensus Rating
Autolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Autolus Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.57% of the outstanding shares of Autolus Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Autolus Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Autolus Therapeutics has recently increased by 32.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Autolus Therapeutics does not currently pay a dividend.
Dividend Growth
Autolus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AUTL.

2.4

News and Social Media Coverage

News Sentiment
Autolus Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Autolus Therapeutics this week, compared to 3 articles on an average week.
Search Interest
8 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Autolus Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Autolus Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Autolus Therapeutics has a P/B Ratio of 7.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AUTL Stock News Headlines

April 14, 2024 | americanbankingnews.com

Needham & Company LLC Reaffirms "Buy" Rating for Autolus Therapeutics (NASDAQ:AUTL)

April 12, 2024 | markets.businessinsider.com

Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | americanbankingnews.com

Autolus Therapeutics (NASDAQ:AUTL) Price Target Raised to $11.00 at Truist Financial

April 9, 2024 | investing.com

Truist raises Autolus Therapeutics stock target on market lead potential

April 2, 2024 | finance.yahoo.com

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

April 1, 2024 | globenewswire.com

Autolus Therapeutics Announces Changes to its Board of Directors

March 25, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 18, 2024 | markets.businessinsider.com

Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views

March 17, 2024 | finance.yahoo.com

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-cel

March 15, 2024 | finance.yahoo.com

Q4 2023 Autolus Therapeutics PLC Earnings Call

March 15, 2024 | finance.yahoo.com

Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

March 15, 2024 | finanznachrichten.de

Autolus Therapeutics plc: Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

March 15, 2024 | msn.com

Autolus Therapeutics FY 2023 Earnings Preview

March 14, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)

March 14, 2024 | finance.yahoo.com

Autolus Therapeutics PLC Reports Full Year 2023 Financial Results

March 14, 2024 | seekingalpha.com

Autolus Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation

March 14, 2024 | msn.com

Autolus Therapeutics GAAP EPS of -$1.20 misses by $0.10, revenue of $1.69M misses by $0.01M

March 14, 2024 | globenewswire.com

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

March 13, 2024 | benzinga.com

Autolus Therapeutics's Earnings Outlook

March 12, 2024 | globenewswire.com

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

March 11, 2024 | finance.yahoo.com

Autolus Therapeutics announces publication in Blood Cancer Journal

March 9, 2024 | finance.yahoo.com

AUTL Jun 2024 10.000 call

March 1, 2024 | ca.finance.yahoo.com

AUTL Mar 2024 2.500 call

February 29, 2024 | globenewswire.com

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

See More Headlines

Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AUTL
CUSIP: N/A
CIK: 1730463
Web: www.autolus.com
Phone: 442038296230
Fax: N/A
Employees: 463
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.16
High Stock Price Target: $11.00
Low Stock Price Target: $4.80
Potential Upside/Downside: +70.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-208,380,000.00
Net Margins: N/A
Pretax Margin: -12,273.38%
Return on Equity: -105.75%
Return on Assets: -49.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.15
Quick Ratio: 6.15

Sales & Book Value

Annual Sales: $1.70 million
Price / Sales: 750.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.64 per share
Price / Book: 7.50

Miscellaneous

Outstanding Shares: 265,930,000
Free Float: 197,583,000
Market Cap: $1.28 billion
Optionable: Optionable
Beta: 1.90

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Christian Martin Itin Ph.D. (Age 60)
CEO & Director
Comp: $2.39M
Dr. Martin Pule M.D. (Age 52)
MBBS, Founder, Senior VP & Chief Scientific Officer
Mr. Robert F. Dolski (Age 53)
Senior VP & CFO
Mr. Christopher Vann (Age 59)
Senior VP & COO
Mr. David Brochu (Age 68)
Senior VP & Chief Technical Officer
Mr. Alexander Swan (Age 59)
Senior VP & Chief Human Resources Officer
Mr. Brent Rice (Age 58)
Senior VP, Chief Commercial Officer & Site Head of US
Ms. Olivia Manser
Director of Investor Relations
Mr. Alex Driggs
Senior VP of Legal Affairs & General Counsel and Secretary
Dr. Chris Williams (Age 44)
Senior VP & Chief Business Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AUTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AUTL shares.
View AUTL analyst ratings or view top-rated stocks.
What is Autolus Therapeutics' stock price target for 2024?: 5 Wall Street research analysts have issued 12 month price targets for Autolus Therapeutics' shares. Their AUTL share price targets range from $4.80 to $11.00. On average, they expect the company's stock price to reach $8.16 in the next year. This suggests a possible upside of 70.0% from the stock's current price.
View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts.
How have AUTL shares performed in 2024?: Autolus Therapeutics' stock was trading at $6.44 on January 1st, 2024. Since then, AUTL shares have decreased by 25.5% and is now trading at $4.80.
View the best growth stocks for 2024 here.
When is Autolus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUTL earnings forecast.
How were Autolus Therapeutics' earnings last quarter?: Autolus Therapeutics plc (NASDAQ:AUTL) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.18.
What ETFs hold Autolus Therapeutics' stock?: ETFs with the largest weight of Autolus Therapeutics (NASDAQ:AUTL) stock in their portfolio include Harbor Disruptive Innovation ETF (INNO).Range Cancer Therapeutics ETF (CNCR).

What other stocks do shareholders of Autolus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD).
When did Autolus Therapeutics IPO?: Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.
Who are Autolus Therapeutics' major shareholders?: Autolus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perpetual Ltd (0.84%).
How do I buy shares of Autolus Therapeutics?: Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUTL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

Autolus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Autolus Therapeutics Stock (NASDAQ:AUTL)

AUTL Stock Price History

AUTL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

AUTL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™